<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357121</url>
  </required_header>
  <id_info>
    <org_study_id>15-000018</org_study_id>
    <secondary_id>JCCCID534</secondary_id>
    <nct_id>NCT02357121</nct_id>
  </id_info>
  <brief_title>Focal Laser Ablation of Prostate Tissue</brief_title>
  <acronym>FLA</acronym>
  <official_title>Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jean Perkins Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pilot, feasibility/exploratory study to evaluate the safety of laser&#xD;
      interstitial thermal therapy (LITT) using Visualase in the focal ablation of prostate tissue&#xD;
      and to gather data for the design of future studies. Intra-procedure temperature and&#xD;
      concurrent rectal wall thermistor monitoring will be performed for internal validation.&#xD;
      Subjects will be monitored for adverse events, and health-related quality of life (HRQOL)&#xD;
      questionnaires will be obtained. Post-treatment MRI and biopsies will be obtained to evaluate&#xD;
      histologic and radiologic changes. Biomarker (PSA, PCA3 and PHI) kinetics will also be&#xD;
      monitored.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">August 20, 2019</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of focal laser treatment using LITT: Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with adverse events will be collected in the 12 month follow-up period to assess safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of focal laser ablation of prostate tissue using the LITT system.</measure>
    <time_frame>12 months</time_frame>
    <description>MRI changes will be determined at 6 and 12 months post FLA to assess efficacy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Laser ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patient will undergo focal ablation of prostate tissue utilizing laser energy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Focal Laser Ablation</intervention_name>
    <description>Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance</description>
    <arm_group_label>Laser ablation</arm_group_label>
    <other_name>laser treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects with untreated organ confined prostate cancer (clinical stage ≤ T2b, Gleason&#xD;
             ≤ 3+4)&#xD;
&#xD;
          -  Negative metastatic workup with bone scan and CT abdomen/pelvis, within 6 months of&#xD;
             study treatment, if indicated by PSA &gt;10&#xD;
&#xD;
          -  Age 40 years to 85 years of age&#xD;
&#xD;
          -  Multi-parametric MRI at UCLA within 6 months of study treatment, demonstrating a&#xD;
&#xD;
               -  Region of interest (ROI) of MRI suspicion level 3 or higher&#xD;
&#xD;
               -  MRI-calculated prostate volume 25cc to 100cc&#xD;
&#xD;
          -  Transrectal ultrasound-guided biopsy with ≥ 10 systematic biopsy cores and ≥ 2&#xD;
             MRI-ultrasound fusion targeted biopsy cores from above MRI-derived ROI&#xD;
&#xD;
               -  Histologically-confirmed adenocarcinoma from targeted biopsy cores&#xD;
&#xD;
               -  Overall Gleason score not to exceed 3+4&#xD;
&#xD;
          -  Subjects desire focal therapy and decline conventional treatment (active surveillance,&#xD;
             radical prostatectomy, radiation therapy, cryosurgery and hormone therapy)&#xD;
&#xD;
          -  Signed informed consent for the FLA treatment through the 12 month follow up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant cancer outside of MRI target (ROI) area, defined as Gleason score &gt;&#xD;
             3+4&#xD;
&#xD;
               -  &lt; 10 years life expectancy&#xD;
&#xD;
               -  American Society of Anesthesiologists (ASA) criteria of IV or higher&#xD;
&#xD;
               -  Unfit for conscious sedation anesthesia&#xD;
&#xD;
               -  Active bleeding disorder as determined by abnormal prothrombin time, partial&#xD;
                  thromboplastin time, INR or platelet count (as determined by institutional lab&#xD;
                  parameters) at the time of screening&#xD;
&#xD;
               -  Use of coumadin or any other anticoagulant, unless anticoagulation can be&#xD;
                  temporarily reversed or stopped for a window of at least 7 days peri-procedure&#xD;
&#xD;
               -  Active urinary tract infection&#xD;
&#xD;
               -  Prostate abscess, chronic or acute prostatitis, or neurogenic bladder&#xD;
&#xD;
               -  Any prior treatment for prostate cancer&#xD;
&#xD;
                    -  Radical prostatectomy&#xD;
&#xD;
                    -  Radiation therapy (external beam or brachytherapy)&#xD;
&#xD;
                    -  Cryotherapy&#xD;
&#xD;
                    -  High intensity focused ultrasound treatment&#xD;
&#xD;
                    -  Photodynamic therapy&#xD;
&#xD;
                    -  Androgen deprivation therapy&#xD;
&#xD;
               -  Prior prostate, bladder neck, or urethral stricture surgery&#xD;
&#xD;
                    -  Any prostate debulking procedure, including: transurethral resection of&#xD;
                       prostate, photovaporization, or electrovaporization&#xD;
&#xD;
                    -  Transurethral incision of bladder neck&#xD;
&#xD;
                    -  Urethral stricture dilation or reconstruction&#xD;
&#xD;
               -  Any current 5-alpha reductase inhibitors (history of use ≥ 3 months prior to MRI&#xD;
                  is acceptable)&#xD;
&#xD;
               -  Prior significant rectal surgery (hemorrhoidectomy is acceptable)&#xD;
&#xD;
               -  Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding&#xD;
                  insertion of transrectal device&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Urinary tract or rectal fistula&#xD;
&#xD;
               -  Any contraindication to MRI (contrast allergy severe claustrophobia,&#xD;
                  MRI-incompatible prosthesis)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Marks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

